Literature DB >> 22217540

The interaction of PKN3 with RhoC promotes malignant growth.

Keziban Unsal-Kacmaz1, Shoba Ragunathan, Edward Rosfjord, Stephen Dann, Erik Upeslacis, Mary Grillo, Richard Hernandez, Fiona Mack, Anke Klippel.   

Abstract

PKN3 is an AGC-family protein kinase implicated in growth of metastatic prostate cancer cells with phosphoinositide 3-kinase pathway deregulation. The molecular mechanism, however, by which PKN3 contributes to malignant growth and tumorigenesis is not well understood. Using orthotopic mouse tumor models, we now show that inducible knockdown of PKN3 protein not only blocks metastasis, but also impairs primary prostate and breast tumor growth. Correspondingly, overexpression of exogenous PKN3 in breast cancer cells further increases their malignant behavior and invasiveness in-vitro. Mechanistically, we demonstrate that PKN3 physically interacts with Rho-family GTPases, and preferentially with RhoC, a known mediator of tumor invasion and metastasis in epithelial cancers. Likewise, RhoC predominantly associates with PKN3 compared to its closely related PKN family members. Unlike the majority of Rho GTPases and PKN molecules, which are ubiquitously expressed, both PKN3 and RhoC show limited expression in normal tissues and become upregulated in late-stage malignancies. Since PKN3 catalytic activity is increased in the presence of Rho GTPases, the co-expression and preferential interaction of PKN3 and RhoC in tumor cells are functionally relevant. Our findings provide novel insight into the regulation and function of PKN3 and suggest that the PKN3-RhoC complex represents an attractive therapeutic target in late-stage malignancies.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22217540      PMCID: PMC5528337          DOI: 10.1016/j.molonc.2011.12.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  56 in total

1.  Dissection of a nuclear localization signal.

Authors:  M R Hodel; A H Corbett; A E Hodel
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 2.  Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm.

Authors:  Alexandra C Newton
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

3.  The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Authors:  Paraic A Kenny; Genee Y Lee; Connie A Myers; Richard M Neve; Jeremy R Semeiks; Paul T Spellman; Katrin Lorenz; Eva H Lee; Mary Helen Barcellos-Hoff; Ole W Petersen; Joe W Gray; Mina J Bissell
Journal:  Mol Oncol       Date:  2007-06       Impact factor: 6.603

4.  Multiple interactions of PRK1 with RhoA. Functional assignment of the Hr1 repeat motif.

Authors:  P Flynn; H Mellor; R Palmer; G Panayotou; P J Parker
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

5.  Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase.

Authors:  P Flynn; H Mellor; A Casamassima; P J Parker
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

6.  Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development.

Authors:  Claire Marionnet; Claude Lalou; Karine Mollier; Marjorie Chazal; Gisele Delestaing; Delphine Compan; Olivier Verola; Catherine Vilmer; Jerome Cuminet; Louis Dubertret; Nicole Basset-Séguin
Journal:  Oncogene       Date:  2003-05-29       Impact factor: 9.867

7.  A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.

Authors:  Eric Metzger; Judith M Müller; Stefano Ferrari; Reinhard Buettner; Roland Schüle
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

8.  Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma.

Authors:  Yasunori Shikada; Ichiro Yoshino; Tatsuro Okamoto; Seiichi Fukuyama; Toshifumi Kameyama; Yoshihiko Maehara
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

9.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.

Authors:  H Suwa; G Ohshio; T Imamura; G Watanabe; S Arii; M Imamura; S Narumiya; H Hiai; M Fukumoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.

Authors:  G Fritz; C Brachetti; F Bahlmann; M Schmidt; B Kaina
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more
  24 in total

1.  A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification.

Authors:  Christopher M Browne; Baishan Jiang; Scott B Ficarro; Zainab M Doctor; Jared L Johnson; Joseph D Card; Sindhu Carmen Sivakumaren; William M Alexander; Tomer M Yaron; Charles J Murphy; Nicholas P Kwiatkowski; Tinghu Zhang; Lewis C Cantley; Nathanael S Gray; Jarrod A Marto
Journal:  J Am Chem Soc       Date:  2018-12-20       Impact factor: 15.419

Review 2.  Toward understanding RhoGTPase specificity: structure, function and local activation.

Authors:  Antje Schaefer; Nathalie R Reinhard; Peter L Hordijk
Journal:  Small GTPases       Date:  2014

Review 3.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

4.  Protein kinase N3 deficiency impedes PI3-kinase pathway-driven leukemogenesis without affecting normal hematopoiesis.

Authors:  M Kraus; B Dolinski; T W Rosahl; J A Magee
Journal:  Leukemia       Date:  2014-09-19       Impact factor: 11.528

5.  The interaction of PKN3 with RhoC promotes malignant growth.

Authors:  Keziban Unsal-Kacmaz; Shoba Ragunathan; Edward Rosfjord; Stephen Dann; Erik Upeslacis; Mary Grillo; Richard Hernandez; Fiona Mack; Anke Klippel
Journal:  Mol Oncol       Date:  2011-12-28       Impact factor: 6.603

6.  RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.

Authors:  Erin M Griner; Garrett M Dancik; James C Costello; Charles Owens; Sunny Guin; Michael G Edwards; David L Brautigan; Dan Theodorescu
Journal:  Mol Cancer Res       Date:  2014-12-16       Impact factor: 5.852

7.  PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors.

Authors:  He Zhu; Scott B Ficarro; William M Alexander; Laura E Fleming; Guillaume Adelmant; Tinghu Zhang; Matthew Willetts; Jens Decker; Sven Brehmer; Michael Krause; Michael P East; Nathanael S Gray; Gary L Johnson; Gary Kruppa; Jarrod A Marto
Journal:  Anal Chem       Date:  2021-10-04       Impact factor: 8.008

8.  Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

Authors:  Christopher R M Asquith; Louisa Temme; Michael P East; Tuomo Laitinen; Julie Pickett; Frank E Kwarcinski; Parvathi Sinha; Carrow I Wells; Gary L Johnson; Reena Zutshi; David H Drewry
Journal:  ChemMedChem       Date:  2022-05-09       Impact factor: 3.540

Review 9.  Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.

Authors:  Micah D K Glasgow; Mahavir B Chougule
Journal:  J Biomed Nanotechnol       Date:  2015-11       Impact factor: 4.099

10.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.